Fabrication and Short-Term in Vivo Performance of a Natural Elastic Lamina-Polymeric Hybrid Vascular Graft.
Fabrication and Short-Term in Vivo Performance of a Natural Elastic Lamina-Polymeric Hybrid Vascular Graft.
复制标题
DOI：
10.1021/acsami.5b03892
复制
发表时间：
2015-07
影响因子：
9.5
通讯作者：
Connor McCarthy;Danielle C Ahrens;David Joda;Tyler E. Curtis;Patrick K Bowen;Roger J. Guillory;Shu Q. Liu;F. Zhao;M. Frost;J. Goldman
中科院分区：
文献类型：
--
作者：
Connor McCarthy;Danielle C Ahrens;David Joda;Tyler E. Curtis;Patrick K Bowen;Roger J. Guillory;Shu Q. Liu;F. Zhao;M. Frost;J. Goldman
尽管在人造血管移植物的开发方面已经取得了重大进展，但是小直径移植物仍然遭受过度血小板活化、血栓形成、平滑肌细胞内膜增生和再狭窄的高发生率。最近的发现表明，天然弹性膜的优良血液接触性能已经提高了脱细胞弹性膜可以有效地用作工程血管移植物中的专利血液接触表面的可能性。然而，单独的弹性膜缺乏作为可行的血管移植物所必需的机械性能。在这里，我们已经筛选了广泛的可生物降解和生物稳定的医用级聚合物，其粘附到弹性膜的外表面的能力，并允许在大鼠腹主动脉中植入后的细胞再增殖。我们展示了一种新的方法，用于制造弹性层聚合物混合小直径血管移植物，并确定聚醚氨酯（PEU 1074A）作为理想的为此目的。体内结果表明，移植物在21天内保持通畅，血栓形成较低，炎症轻微，移植物腔表面总体上没有平滑肌细胞增生。这些结果为开发小直径血管移植物提供了新的方向，这些血管移植物由于缺乏免疫反应而可批量生产、货架稳定且普遍相容，并抑制非自体材料常见的移植物内再狭窄反应。
Although significant advances have been made in the development of artificial vascular grafts, small-diameter grafts still suffer from excessive platelet activation, thrombus formation, smooth muscle cell intimal hyperplasia, and high occurrences of restenosis. Recent discoveries demonstrating the excellent blood-contacting properties of the natural elastic lamina have raised the possibility that an acellular elastic lamina could effectively serve as a patent blood-contacting surface in engineered vascular grafts. However, the elastic lamina alone lacks the requisite mechanical properties to function as a viable vascular graft. Here, we have screened a wide range of biodegradable and biostable medical-grade polymers for their ability to adhere to the outer surface of the elastic lamina and allow cellular repopulation following engraftment in the rat abdominal aorta. We demonstrate a novel method for the fabrication of elastic lamina-polymeric hybrid small-diameter vascular grafts and identify poly(ether urethane) (PEU 1074A) as ideal for this purpose. In vivo results demonstrate graft patency over 21 days, with low thrombus formation, mild inflammation, and the general absence of smooth muscle cell hyperplasia on the graft's luminal surface. The results provide a new direction for developing small-diameter vascular grafts that are mass-producible, shelf-stable, and universally compatible due to a lack of immune response and inhibit the in-graft restenosis response that is common to nonautologous materials.